Best of Hematology and Breast Cancer 2025, Houston

Houston, TX US
January 24, 2025 to January 25, 2025

The Best of Hematology and Breast Cancer 2025 conference in Houston is a CME-accredited, in-person event providing healthcare professionals with the latest updates in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting (ASH24) and the San Antonio Breast Cancer Symposium (SABCS24), the conference features expert presentations on recent research and its clinical implications.

Focusing on a multidisciplinary approach, the event aims to integrate new advancements into patient-centered care. Designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other professionals, attendees will engage with colleagues and experts to critically evaluate data and improve patient outcomes.

The Best of Hematology and Breast Cancer 2025, Houston, is an educational activity planned by the Binaytara Foundation. Neither Binaytara Foundation nor this activity are affiliated with the American Society of Hematology (ASH) or the San Antonio Breast Cancer Symposium (SABCS).

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Co-Chairs:

Shilpan Shah, MD - Houston Methodist Oncology Partners

Julie Nangia, MD - Baylor College of Medicine

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Summarize the latest updates from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
  2. Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24.
  3. Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH24 and SABCS24 that have influenced current standards of care.
  4. Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH24 and SABCS24 into patient management for hematologic disorders and breast cancer.
  5. Apply emerging data from clinical trials and updated expert guidelines from ASH24 and SABCS24 to individualize patient management strategies.

Hotel Room Reservation

A limited number of guestrooms are reserved at the Intercontinental Houston for the participants of this meeting at a discounted rate of $179 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Tuesday, December 22, 2024.

Booking Link

Parking

Overnight self-parking is $29 per vehicle, per night.

Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
08/06/2024
Course expires: 
04/06/2025
Event starts: 
01/24/2025 - 4:00pm PST
Event ends: 
01/25/2025 - 4:30pm PST
Cost:
$250.00

DAY 1 – Friday, January 24, 2025

All times are listed in Central Standard Time (CST)

02:00 PM – 03:00 PM  Registration, Exhibits, & Networking


03:00 PM – 04:00 PM  Session 1: Classical Hematology - Cytopenias

Session Chair: Lawrence Rice, MD & Devesh Pandya, MD

03:00 PM – 03:15 PM  HUS/TTP - Shubham Adroja, MD

03:15 PM – 03:30 PM  PNH - 

03:30 PM – 03:45 PM  Anemia - Akhil Mehta, DO, MPH

03:45 PM – 04:00 PM  Bone Marrow Failure Vikram Dhillon, DO, MBA


04:00 PM – 05:00 PM  Session 2: Bleeding and Clotting Disorder

Session Chair: Jenny Petkova, MD

04:00 PM – 04:30 PM  Bleeding Disorders - Jenny Petkova, MD

04:30 PM – 05:00 PM  Clotting Disorders - Senthil Sukumar, MD, MS


05:00 PM – 06:00 PM  Reception

 

DAY 2 – Saturday, January 25, 2025

07:00 AM – 08:00 AM  Registration, Exhibits & Breakfast


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:30 AM – 09:30 AM  Session 3: Acute Leukemia

Session Chair: Shilpan Shah, MD

08:30 AM – 09:00 AM  Acute Myeloid Leukemia/MDS - Martha Mims, MD, PhD

09:00 AM – 09:30 AM  Acute Lymphoblastic Leukemia - Nitin Jain, MD


09:30 AM – 10:45 AM  Session 4: Lymphoma

Session Chair: 

09:30 AM – 09:55 AM  B-Cell Lymphoma - Sravanti Teegavarapu, MD

09:55 AM – 10:20 AM  CLL - Shilpan Shah, MD

10:20 AM – 10:45 AM  T-Cell Lymphoma - 


10:45 AM – 11:00 AM  Break & Exhibits


11:00 AM – 12:00 PM  Session 5: Multiple Myeloma

Session Chair: Siddhartha Ganguly, MD, FACP

11:00 AM – 11:30 AM  Frontline Therapy of Multiple Myeloma - Carrie Yuen, MD

11:30 AM – 12:00 PM  Relapsed/Recurrent Multiple Myeloma - Neeraj Saini, MD


12:00 PM – 01:00 PM  Lunch & Exhibits


01:00 PM – 02:00 PM Session 6: Hematologic Malignancies

Session Chairs: 

01:00 PM – 01:30 PM  Challenging Cases in Leukemia - Jayastu Senapati, MD, MBBS

01:30 PM – 02:00 PM  Cellular Therapy - 


02:00 PM – 02:15 PM  Break & Exhibits


02:15 PM – 03:45 PM  Session 7: Updates in Management of Breast Cancer

Session Chair: Julie Nangia, MD

02:15 PM – 02:45 PM  HER2 Positive Breast Cancer - Akshjot Puri, MD

02:45 PM – 03:15 PM  Triple Negative and HER2 Low Breast Cancer - Natalie Chen, MD

03:15 PM – 03:45 PM  ER/PR Positive Breast Cancer - Michelina Cairo, MD


03:45 PM – 04:35 PM  Session 8: Tumor Board-Style Case-Based Discussion: Breast Cancer

Session Chair: Julie Nangia, MD

03:45 PM – 03:55 PM  Metaplastic Breast Cancer - Yuan Gao, MD

03:55 PM – 04:05 PM  Low/Very Low HER2 Disease - Nabiha Aziz, MD

04:05 PM – 04:15 PM  Surgery: Less is More - 

04:15 PM – 04:25 PM  Radiation: Keep it Simple - 

04:25 PM – 04:35 PM  DCIS - Tamer Khasab, MD


04:35 PM  Adjourn

InterContinental Houston
6750 Main Street
Houston, TX 77030
United States

Hotel Room Reservation

A limited number of guestrooms are reserved at the Intercontinental Houston for the participants of this meeting at a discounted rate of $179 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Tuesday, December 17, 2024.

Parking

Overnight self-parking is $29 per vehicle, per night.

Faculty information coming soon

 

Conference Chair(s)

Julie Nangia, MD

has no relevant financial relationships to disclose at this time.

Shilpan Shah

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Siddhartha Ganguly, MD, FACP

has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with Astra Zeneca;.
has a financial relationship (Financial Support) with Sanofi Genzyme;.

Julie Nangia, MD

has no relevant financial relationships to disclose at this time.

Devesh Pandya

has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with Guardant Health;.
has a financial relationship (Other) with Jazz Pharmaceuticals;.
has a financial relationship (Other) with Myriad;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with SeaGen;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with EMD Serono;.
has a financial relationship (Other) with Janssen;.

Jenny petkova

has no relevant financial relationships to disclose at this time.

Lawrence Rice

has a financial relationship (Professional Services) with Alexion;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Agios;.

Shilpan Shah

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Natalie Chen, MD PhD

has no relevant financial relationships to disclose at this time.

Nitin Jain, MD

has a financial relationship (Gift) with Pharmacyclics;.
has a financial relationship (Gift) with AstraZeneca;.
has a financial relationship (Gift) with Cellectis;.
has a financial relationship (Gift) with Genentech;.
has a financial relationship (Gift) with Beigene;.
has a financial relationship (Gift) with AbbVie;.
has a financial relationship (Gift) with Precision Bio;.
has a financial relationship (Gift) with Janssen;.
has a financial relationship (Gift) with Kite;.
has a financial relationship (Gift) with Fate Therapeutics;.

Martha Mims

has a financial relationship (Stock) with Amgen;.
has a financial relationship (Stock) with Biogen IDEC;.

Jenny petkova

has no relevant financial relationships to disclose at this time.

Akshjot Puri, MD

has no relevant financial relationships to disclose at this time.

Shilpan Shah

has no relevant financial relationships to disclose at this time.

Senthil Sukumar, MD MS

has a financial relationship (Grant Or Contract) with Sanofi-Genzyne;.

Carrie Hau Lai Yuen, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Yuan Gao

has no relevant financial relationships to disclose at this time.

Tamer Khashab, MD

has no relevant financial relationships to disclose at this time.

Jayastu Senapati, MBBS, MD, DM

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • Exact Sciences
  • Incyte

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$250.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.